Nearly 200,000 doses of a twice-yearly HIV shot are out in Africa. Supply is the limit.

Nine African countries have now launched the long-acting HIV prevention injection lenacapavir, and early rollout data presented this month put the scale of the effort in concrete numbers: 191,620 doses administered, roughly 66,000 people newly started on the drug, across some 900 clinical sites, with more than 10,000 healthcare providers trained to deliver it [s1]. That is about 14 percent of the doses countries are targeting to deliver in 2026 [s1].

It is also, in at least two of those nine countries, already outpacing what manufacturers can supply.

Where the doses have gone

Lenacapavir is administered twice yearly by injection and has shown near-complete protection against HIV acquisition in prior clinical trials, which is why its rollout across high-incidence settings has drawn close attention since regulatory approval. The countries with programs underway are Eswatini, Kenya, Lesotho, Mozambique, Nigeria, South Africa, Uganda, Zambia and Zimbabwe [s1]. South Africa alone is projected to administer 345,000 shots over the course of 2026 [s1].

Uptake data reported from individual countries show the drug reaching the populations HIV prevention programs have struggled hardest to serve. In Eswatini, close to 1,000 adolescent girls and young women and roughly 700 pregnant or breastfeeding women have started lenacapavir [s1]. In Malawi, more than half of 303 initiations were among women, including three pregnant and ten breastfeeding women [s1]. Kenya has recorded more than 4,000 initiations among key populations, and Mozambique nearly 10,000 across three provinces [s1].

Where it is already breaking down

The rollout's supply constraints are not evenly distributed, and the two clearest examples illustrate different failure modes. In Eswatini, inconsistent medication availability forced the national program to set aside 10,000 doses specifically to cover people already on lenacapavir and due for their next injection — a decision that meant halting new patient initiations to protect continuity of care for existing ones [s1]. In Mozambique, a recent decline in uptake has been attributed not to falling demand but to limited supply of both the drug itself and the dried blood spot testing materials needed to monitor patients on it, even as demand for the program has held steady [s1].

Both cases point to the same underlying dynamic: national programs built ambitious 2026 targets around an assumption of steady supply, and manufacturing has not kept pace with the rollout speed those targets assumed.

The scale-up problem behind the numbers

Lenacapavir's manufacturer and international partners have set a joint goal of reaching several million people across low- and middle-income countries with the drug over the next few years, a target premised on rapidly increasing production volume. The gap now visible in Eswatini and Mozambique is an early, concrete signal of what happens when program ambition outruns that production curve in real time, rather than in a planning document.

It is also a familiar pattern in global health product launches: the first-mover countries with the strongest health system infrastructure — the ones best positioned to launch fast — are often the ones that hit supply ceilings first, precisely because they built programs sized to serve demand rather than to match whatever allocation arrived. Whether manufacturers can catch up before the credibility of national program targets erodes further is, at this stage, an open operational question rather than a resolved one.

"Our goal is not just to launch LEN. It's to get countries to use it strategically," Ingrid Katz, director of the Yale Institute for Global Health, said in comments on the rollout data [s1]. Strategic use is harder to sustain when a program cannot promise its own existing patients a guaranteed next dose.

What to watch

Whether Eswatini's paused initiations resume once its reserved-dose buffer stabilizes, and whether Mozambique's testing-supply shortfall is resolved separately from its drug-supply shortfall, since the two require different fixes. More broadly, whether the roughly 14-percent pace toward 2026 targets accelerates as more manufacturing capacity comes online, or whether supply-driven pauses spread to additional countries as the remaining seven launch programs scale toward their own targets. This article describes program-level rollout data, not individual clinical guidance; people considering HIV prevention options should speak with a health provider about what is available to them.

Sources

• [s1] aidsmap, "Nearly 200,000 lenacapavir shots given across Africa, but supply issues pose challenges," 29 July 2026. https://www.aidsmap.com/news/jul-2026/nearly-200000-lenacapavir-shots-given-across-africa-supply-issues-pose-challenges